Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp (NQ: LEXX ) 2.610 +0.020 (+0.77%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Lexaria Bioscience Corp < Previous 1 2 3 4 5 Next > Lexaria Bioscience Optimistic About Upcoming Hypertension Study March 28, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Via Benzinga Lexaria's IP Portfolio Grows Following Receipt Of 24th Granted Patent March 22, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria has received a new patent entitled “Compositions... Via Benzinga Lexaria Bioscience Commences DehydraTECH-CBD Epilepsy Research Program March 16, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Via Benzinga Lexaria Bioscience Receives Award For Oral Nicotine Compound Patent March 09, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience (NASDAQ: LEXX), a... Via Benzinga Studies Advance Lexaria Bioscience's Tech For Improving Pharmaceutical Drugs March 07, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience is dedicated to... Via Benzinga Lexaria's DehydraTECH(TM) Demonstrates Faster Delivery Of Sildenafil March 04, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX)... Via Benzinga Lexaria Emphasizes Oral Cannabinoid Benefits Following SARS-CoV-2 Study January 28, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Via Benzinga Lexaria Bioscience Optimistic Of Positive Study Results February 28, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... Via Benzinga Lexaria Optimistic About Expanded DehydraTECH Investigations February 23, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria just announced ground-breaking... Via Benzinga Lexaria World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Tech February 22, 2022 Photo by Shelby Ireland on Unsplash Via Benzinga Following Sildenafil Study, Lexaria Announces Plans For More Studies In 2022 February 17, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria’s animal study could be... Via Benzinga Lexaria's DehydraTECH(TM) To Be Evaluated As Treatment For Multiple Conditions February 14, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX)... Via Benzinga Lexaria Technology Shows Promise In Improving Performance Of ED Drugs February 11, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Health and wellness drug bio-... Via Benzinga Lexaria CEO Summarizes 2021 Milestones in Letter to Shareholders February 09, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. In 2021, Lexaria conducted several main studies evaluating... Via Benzinga Lexaria Bioscience Announces Significant Findings From Sildenafil Animal Study February 03, 2022 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reported positive findings in its recent animal study. Via Benzinga Lexaria CEO Offers A Glimpse Into Company's Unique Tech On EDGE Podcast February 01, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Chris Bunka, the Chairman and CEO of Lexaria, featured on the... Via Benzinga Lexaria Bioscience Marks Great Start to its 2022 R&D Programs January 21, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria received independent review... Via Benzinga Lexaria Bioscience Comments on Study Examining Cannabinoids and SARS-CoV-2 January 19, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience (NASDAQ: LEXX), a... Via Benzinga Lexaria Bioscience Leveraging DehydraTECH(TM) for More Effective Oral Medicine January 18, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX... Via Benzinga Lexaria Bioscience Celebrates Productive Year for Blood Pressure Drug Solution January 12, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience’s ongoing... Via Benzinga Lexaria Bioscience (NASDAQ: LEXX) Receives Independent Review Board Approval for Human Study January 11, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria has received approval from the... Via Benzinga 12 Health Care Stocks Moving In Friday's After-Market Session January 07, 2022 Gainers ContraFect (NASDAQ:CFRX) stock mo... Via Benzinga Lexaria Bioscience Increases Investor Visibility with SRAX January 07, 2022 This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The strategic move to incorporate... Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session January 06, 2022 Gainers ContraFect (NASDAQ:CFRX) stock in... Via Benzinga Lexaria Bioscience Announces Approval from Independent Review for DehydraTECH-CBD Study December 30, 2021 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has received Independent Review Board (“IRB”) approval for its planned DehydraTECH-... Via Benzinga Lexaria Bioscience Expects Study Results to Show Patented Tech's Value in Treating Hypertension December 28, 2021 Lexaria Bioscience is preparing to file an Investigational New Drug application with the U.S. Food and Drug Administration for its patented technology’s use in treating... Via Benzinga Lexaria Bioscience Announces Major Discovery; Increasing Effectiveness of Orally Administered CBD December 23, 2021 In a recent human clinical trial, HYPER-H21-2, DehydraTECH-CBD reduced arterial stiffness, potentially broadening Lexaria’s application’s ability to treat... Via Benzinga Lexaria's DehydraTECH(TM) CBD Found to Reduce Arterial Stiffness in Study December 17, 2021 Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood... Via Benzinga Lexaria Bioscience Committed to Innovation and Improving Quality of Life December 15, 2021 Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021 The event came right after the company announced human clinical... Via Benzinga Lexaria's Upcoming R&D Programs Targeting Global Markets Exceeding $160B December 13, 2021 Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022 The programs are designed to explore the ability of the company’s... Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.